Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 258

1.

High-dose therapy and autologous stem cell transplantation for relapsed or high-risk diffuse large B-cell lymphoma: a nationwide survey.

Kim SW, Asakura Y, Tajima K, Iwai T, Taji H, Chou T, Morishima Y, Suzumiya J, Sakamaki H, Suzuki R, Fukuda T.

Int J Hematol. 2019 Nov 16. doi: 10.1007/s12185-019-02772-1. [Epub ahead of print]

PMID:
31732878
2.

DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 study.

Miyazaki K, Asano N, Yamada T, Miyawaki K, Sakai R, Igarashi T, Nishikori M, Ohata K, Sunami K, Yoshida I, Yamamoto G, Takahashi N, Okamoto M, Yano H, Nishimura Y, Tamaru S, Nishikawa M, Izutsu K, Kinoshita T, Suzumiya J, Ohshima K, Kato K, Katayama N, Yamaguchi M; CD5+ DLBCL Treatment Study Group.

Haematologica. 2019 Oct 24. pii: haematol.2019.231076. doi: 10.3324/haematol.2019.231076. [Epub ahead of print]

3.

Successful outcome with reduced-intensity condition regimen followed by allogeneic hematopoietic stem cell transplantation for relapsed or refractory anaplastic large-cell lymphoma.

Fukano R, Mori T, Fujita N, Kobayashi R, Mitsui T, Kato K, Suzuki R, Suzumiya J, Fukuda T, Shindo M, Maseki N, Shimoyama T, Okada K, Inoue M, Inagaki J, Hashii Y, Sato A, Tabuchi K.

Int J Hematol. 2019 Dec;110(6):723-728. doi: 10.1007/s12185-019-02748-1. Epub 2019 Oct 16.

PMID:
31620968
4.

FF-10501 induces caspase-8-mediated apoptotic and endoplasmic reticulum stress-mediated necrotic cell death in hematological malignant cells.

Matsumoto T, Jimi S, Migita K, Terada K, Mori M, Takamatsu Y, Suzumiya J, Hara S.

Int J Hematol. 2019 Nov;110(5):606-617. doi: 10.1007/s12185-019-02722-x. Epub 2019 Aug 12.

PMID:
31407254
5.

Effect of allogeneic hematopoietic cell transplantation for patients with T-prolymphocytic leukemia: a retrospective study from the Adult Lymphoma Working Group of the Japan Society for hematopoietic cell transplantation.

Yamasaki S, Nitta H, Kondo E, Uchida N, Miyazaki T, Ishiyama K, Kiyota M, Matsuoka H, Ichinohe T, Fukuda T, Atsuta Y, Suzumiya J, Suzuki R.

Ann Hematol. 2019 Sep;98(9):2213-2220. doi: 10.1007/s00277-019-03759-y. Epub 2019 Jul 20.

PMID:
31327025
6.

The effectiveness of busulfan-based conditioning regimens for stem cell transplantation against lymphomas in children, adolescents, and young adults in Japan.

Hori D, Kobayashi R, Fujita N, Suzumiya J, Suzuki R, Kato K, Kawata T, Fukuda T, Inoue M, Goto H, Hama A, Iwato K, Okumura H, Eto T, Hashii Y, Atsuta Y, Mitsui T.

Pediatr Blood Cancer. 2019 Oct;66(10):e27918. doi: 10.1002/pbc.27918. Epub 2019 Jul 12.

PMID:
31298481
7.

Clinical outcomes of hepatitis B or C virus infections in patients with malignant lymphoma receiving autologous stem cell transplantation: on behalf of the Adult Lymphoma Working Group of the Japan Society for Haematopoietic Cell Transplantation (JSHCT).

Kato H, Kato K, Kim SW, Fukuda T, Mori T, Sawa M, Ohno Y, Yoshioka S, Iwato Y, Taji H, Onizuka M, Kurahashi S, Ichinohe T, Suzumiya J, Suzuki R.

Br J Haematol. 2019 Sep;186(6):e170-e175. doi: 10.1111/bjh.16050. Epub 2019 Jun 17. No abstract available.

PMID:
31206602
8.

[Ⅱ.Chronic Lymphocytic Leukemia].

Suzumiya J.

Gan To Kagaku Ryoho. 2019 May;46(5):868-873. Japanese. No abstract available.

PMID:
31189806
9.

[Chronic lymphocytic leukemia/ small lymphocytic lymphoma: CLL/SLL].

Suzumiya J.

Rinsho Ketsueki. 2019;60(3):232-233. doi: 10.11406/rinketsu.60.232. Japanese. No abstract available.

PMID:
31068525
10.

Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).

Sunami K, Matsumoto M, Fuchida SI, Omoto E, Takamatsu H, Adachi Y, Choi I, Fujishima N, Kiguchi T, Miyamoto T, Maeda A, Suzumiya J, Yamamura R, Nagafuji K, Nakazato T, Kuroda Y, Yujiri T, Takamatsu Y, Harada M, Akashi K.

Int J Clin Oncol. 2019 Aug;24(8):966-975. doi: 10.1007/s10147-019-01436-8. Epub 2019 Apr 1.

PMID:
30937622
11.

[Cooperation between Clinics and Hospitals Using a Critical Path for G-CSF Prophylaxis in Cancer Chemotherapy].

Takahashi T, Takahashi F, Okada Y, Ito S, Ugata N, Shimasaki Y, Mochida H, Matsuda S, Okada T, Kumanomidou S, Jo Y, Adachi K, Ikejiri F, Onishi C, Kawakami K, Moriyama I, Inoue M, Miyake T, Suzuki R, Suzumiya J.

Gan To Kagaku Ryoho. 2019 Mar;46(3):457-461. Japanese.

PMID:
30914584
12.

Outcome of patients receiving consolidative autologous peripheral blood stem cell transplantation in the frontline treatment of intravascular large B-cell lymphoma: Adult Lymphoma Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Kato K, Mori T, Kim SW, Sawa M, Sakai T, Hashimoto H, Taguchi J, Oyake T, Kurahashi S, Imada K, Ohno H, Tanaka J, Ichinohe T, Atsuta Y, Suzuki R, Suzumiya J.

Bone Marrow Transplant. 2019 Sep;54(9):1515-1517. doi: 10.1038/s41409-019-0491-7. Epub 2019 Feb 26. No abstract available.

PMID:
30809035
13.

Hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma.

Fujita N, Kobayashi R, Atsuta Y, Iwasaki F, Suzumiya J, Sasahara Y, Inoue M, Koh K, Hori T, Goto H, Ichinohe T, Hashii Y, Kato K, Suzuki R, Mitsui T.

Int J Hematol. 2019 Apr;109(4):483-490. doi: 10.1007/s12185-019-02608-y. Epub 2019 Jan 30.

PMID:
30701466
14.

High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma: Data From the Japan Society for Hematopoietic Cell Transplantation Registry.

Kondo E, Ikeda T, Izutsu K, Chihara D, Shimizu-Koresawa R, Fujii N, Sakai T, Kondo T, Kubo K, Kato Y, Akasaka T, Fukuda T, Ichinohe T, Atsuta Y, Suzumiya J, Suzuki R; Adult Lymphoma Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Biol Blood Marrow Transplant. 2019 May;25(5):899-905. doi: 10.1016/j.bbmt.2019.01.020. Epub 2019 Jan 18.

PMID:
30664936
15.

Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory marginal zone lymphoma.

Yamasaki S, Chihara D, Yoshida I, Kohda K, Sawa M, Ago H, Togitani K, Ohno Y, Tanaka J, Fukuda T, Atsuta Y, Suzumiya J, Suzuki R.

Ann Hematol. 2019 Jun;98(6):1521-1523. doi: 10.1007/s00277-018-3587-z. Epub 2018 Dec 17. No abstract available.

PMID:
30560447
16.

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial.

Ogura M, Sancho JM, Cho SG, Nakazawa H, Suzumiya J, Tumyan G, Kim JS, Lennard A, Mariz J, Ilyin N, Jurczak W, Lopez Martinez A, Samoilova O, Zhavrid E, Yañez Ruiz E, Trneny M, Popplewell L, Coiffier B, Buske C, Kim WS, Lee SJ, Lee SY, Bae YJ, Kwak LW.

Lancet Haematol. 2018 Nov;5(11):e543-e553. doi: 10.1016/S2352-3026(18)30157-1.

PMID:
30389036
17.

Correction to: Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma.

Maruyama D, Tsukasaki K, Uchida T, Maeda Y, Shibayama H, Nagai H, Kurosawa M, Suehiro Y, Hatake K, Ando K, Yoshida I, Hidaka M, Murayama T, Okitsu Y, Tsukamoto N, Taniwaki M, Suzumiya J, Tamura K, Yamauchi T, Ueda R, Tobinai K.

Ann Hematol. 2018 Dec;97(12):2529-2530. doi: 10.1007/s00277-018-3455-x.

18.

Correction to: Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory mantle cell lymphoma.

Yamasaki S, Chihara D, Kim SW, Izutsu K, Iwato K, Fukuda T, Uchida N, Amano I, Nakazawa H, Kuroda J, Hashimoto H, Ichinohe T, Kanda Y, Atsuta Y, Suzumiya J, Suzuki R.

Ann Hematol. 2018 Oct;97(10):2013-2014. doi: 10.1007/s00277-018-3450-2.

PMID:
30046847
19.

Identification of the BRAF V600E mutation in Japanese patients with hairy cell leukemia and related diseases using a quenching probe method.

Itamura H, Ide M, Sato A, Sueoka-Aragane N, Sueoka E, Nishida A, Masunari T, Aoki S, Takizawa J, Suzumiya J, Kimura S.

Int J Hematol. 2018 Oct;108(4):416-422. doi: 10.1007/s12185-018-2506-3. Epub 2018 Jul 24.

PMID:
30043333
20.

Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma.

Maruyama D, Tsukasaki K, Uchida T, Maeda Y, Shibayama H, Nagai H, Kurosawa M, Suehiro Y, Hatake K, Ando K, Yoshida I, Hidaka M, Murayama T, Okitsu Y, Tsukamoto N, Taniwaki M, Suzumiya J, Tamura K, Yamauchi T, Ueda R, Tobinai K.

Ann Hematol. 2019 Jan;98(1):131-142. doi: 10.1007/s00277-018-3418-2. Epub 2018 Jul 5. Erratum in: Ann Hematol. 2018 Dec;97(12):2529-2530.

21.

[Chronic lymphocytic leukemia: update on pathophysiology and management].

Suzumiya J.

Rinsho Ketsueki. 2018;59(5):511-520. doi: 10.11406/rinketsu.59.511. Japanese.

PMID:
29877241
22.

How asymptomatic are early cancer patients of five organs based on registry data in Japan.

Nakabayashi N, Hirose M, Suzuki R, Suzumiya J, Igawa M.

Int J Clin Oncol. 2018 Oct;23(5):999-1006. doi: 10.1007/s10147-018-1287-2. Epub 2018 May 21.

PMID:
29785620
23.

Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target.

Dufva O, Kankainen M, Kelkka T, Sekiguchi N, Awad SA, Eldfors S, Yadav B, Kuusanmäki H, Malani D, Andersson EI, Pietarinen P, Saikko L, Kovanen PE, Ojala T, Lee DA, Loughran TP Jr, Nakazawa H, Suzumiya J, Suzuki R, Ko YH, Kim WS, Chuang SS, Aittokallio T, Chan WC, Ohshima K, Ishida F, Mustjoki S.

Nat Commun. 2018 Apr 19;9(1):1567. doi: 10.1038/s41467-018-03987-2.

24.

Cotylenin A and tyrosine kinase inhibitors synergistically inhibit the growth of chronic myeloid leukemia cells.

Ikejiri F, Honma Y, Okada T, Urano T, Suzumiya J.

Int J Oncol. 2018 Jun;52(6):2061-2068. doi: 10.3892/ijo.2018.4350. Epub 2018 Apr 2.

PMID:
29620253
25.

Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory mantle cell lymphoma.

Yamasaki S, Chihara D, Kim SW, Izutsu K, Iwato K, Fukuda T, Uchida N, Amano I, Nakazawa H, Kuroda J, Hashimoto H, Ichinohe T, Kanda Y, Atsuta Y, Suzumiya J, Suzuki R.

Ann Hematol. 2018 Aug;97(8):1445-1452. doi: 10.1007/s00277-018-3318-5. Epub 2018 Apr 2. Erratum in: Ann Hematol. 2018 Oct;97(10):2013-2014.

PMID:
29610968
26.

Current status and progress of lymphoma research in East Asian countries: Introduction and planning.

Suzumiya J.

Int J Hematol. 2018 Apr;107(4):392-394. doi: 10.1007/s12185-018-2425-3. Epub 2018 Feb 28. No abstract available.

PMID:
29492832
27.

TH588, an MTH1 inhibitor, enhances phenethyl isothiocyanate-induced growth inhibition in pancreatic cancer cells.

Ikejiri F, Honma Y, Kasukabe T, Urano T, Suzumiya J.

Oncol Lett. 2018 Mar;15(3):3240-3244. doi: 10.3892/ol.2017.7713. Epub 2017 Dec 29.

28.

A prospective study of palonosetron for prevention of chemotherapy-induced nausea and vomiting in malignant lymphoma patients following highly emetogenic chemotherapy.

Takahashi T, Okada T, Ikejiri F, Ito S, Okada Y, Takahashi F, Kumanomido S, Jo Y, Adachi K, Onishi C, Kawakami K, Miyake T, Inoue M, Suzuki R, Suzumiya J.

Int J Clin Oncol. 2018 Feb;23(1):189-194. doi: 10.1007/s10147-017-1173-3. Epub 2017 Aug 19.

PMID:
28823027
29.

Japanese apricot extract (MK615) potentiates bendamustine-induced apoptosis via impairment of the DNA damage response in lymphoma cells.

Inoue M, Honma Y, Urano T, Suzumiya J.

Oncol Lett. 2017 Jul;14(1):792-800. doi: 10.3892/ol.2017.6219. Epub 2017 May 19.

30.

Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma.

Katsuya H, Shimokawa M, Ishitsuka K, Kawai K, Amano M, Utsunomiya A, Hino R, Hanada S, Jo T, Tsukasaki K, Moriuchi Y, Sueoka E, Yoshida S, Suzushima H, Miyahara M, Yamashita K, Eto T, Suzumiya J, Tamura K.

Blood. 2017 Jul 6;130(1):39-47. doi: 10.1182/blood-2017-01-757542. Epub 2017 May 17.

PMID:
28515095
31.

Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma.

Yamasaki S, Suzuki R, Hatano K, Fukushima K, Iida H, Morishima S, Suehiro Y, Fukuda T, Uchida N, Uchiyama H, Ikeda H, Yokota A, Tsukasaki K, Yamaguchi H, Kuroda J, Nakamae H, Adachi Y, Matsuoka KI, Nakamura Y, Atsuta Y, Suzumiya J.

Bone Marrow Transplant. 2017 Jul;52(7):969-976. doi: 10.1038/bmt.2017.52. Epub 2017 Apr 3.

PMID:
28368379
32.

A multicenter, single-arm, Phase II clinical trial of bendamustine monotherapy in patients with chronic lymphocytic leukemia in Japan.

Ogawa Y, Izutsu K, Kiguchi T, Choi I, Takatsuka Y, Ando K, Suzumiya J; Japanese Bendamustine CLL Study Group.

Int J Hematol. 2017 May;105(5):631-637. doi: 10.1007/s12185-016-2178-9. Epub 2017 Feb 3.

PMID:
28160213
33.

Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan.

Ogura M, Ishizawa K, Maruyama D, Uike N, Ando K, Izutsu K, Terui Y, Imaizumi Y, Tsukasaki K, Suzuki K, Izumi T, Usuki K, Kinoshita T, Taniwaki M, Uoshima N, Suzumiya J, Kurosawa M, Nagai H, Uchida T, Fukuhara N, Choi I, Ohmachi K, Yamamoto G, Tobinai K; Japanese Bendamustine Lymphoma Study Group.

Int J Hematol. 2017 Apr;105(4):470-477. doi: 10.1007/s12185-016-2146-4. Epub 2016 Nov 29.

PMID:
27900638
34.

Outcome differences between children and adolescents and young adults with non-Hodgkin lymphoma following stem cell transplantation.

Kobayashi R, Mitsui T, Fujita N, Osumi T, Aoki T, Aoki K, Suzuki R, Fukuda T, Miyamoto T, Kato K, Nakamae H, Goto H, Eto T, Inoue M, Mori T, Terui K, Onizuka M, Koh K, Koga Y, Ichinohe T, Sawada A, Atsuta Y, Suzumiya J.

Int J Hematol. 2017 Mar;105(3):369-376. doi: 10.1007/s12185-016-2120-1. Epub 2016 Oct 27.

PMID:
27787746
35.
36.

A retrospective study of R-CHOP/CHOP therapy-induced nausea and vomiting in non-Hodgkin's lymphoma patients: a comparison of intravenous and oral 5-HT3 receptor antagonists.

Takahashi T, Kumanomidou S, Takami S, Okada T, Adachi K, Jo Y, Ikejiri F, Onishi C, Kawakami K, Miyake T, Inoue M, Moriyama I, Suzuki R, Suzumiya J.

Int J Hematol. 2016 Sep;104(3):378-83. doi: 10.1007/s12185-016-2041-z. Epub 2016 Jun 16.

PMID:
27312042
37.

Tamoxifen enhances the differentiation-inducing and growth-inhibitory effects of all-trans retinoic acid in acute promyelocytic leukemia cells.

Adachi K, Honma Y, Miyake T, Kawakami K, Takahashi T, Suzumiya J.

Int J Oncol. 2016 Mar;48(3):1095-102. doi: 10.3892/ijo.2016.3348. Epub 2016 Jan 19.

PMID:
26797574
38.

Spontaneous Regression of Intravascular Large B-Cell Lymphoma and Apoptosis of Lymphoma Cells: A Case Report.

Takahashi T, Ikejiri F, Takami S, Okada T, Kumanomidou S, Adachi K, Yumi J, Onishi C, Kawakami K, Moriyama I, Inoue M, Miyake T, Tanaka J, Maruyama R, Suzumiya J.

J Clin Exp Hematop. 2015;55(3):151-6. doi: 10.3960/jslrt.55.151.

39.

Internal tandem duplication mutations in FLT3 gene augment chemotaxis to Cxcl12 protein by blocking the down-regulation of Rho-associated kinase via the Cxcl12/Cxcr4 signaling axis.

Onishi C, Mori-Kimachi S, Hirade T, Abe M, Taketani T, Suzumiya J, Sugimoto T, Yamaguchi S, Kapur R, Fukuda S.

J Biol Chem. 2015 Nov 20;290(47):28356. doi: 10.1074/jbc.A114.568287. No abstract available.

40.

Treatment and survival among 1594 patients with ATL.

Katsuya H, Ishitsuka K, Utsunomiya A, Hanada S, Eto T, Moriuchi Y, Saburi Y, Miyahara M, Sueoka E, Uike N, Yoshida S, Yamashita K, Tsukasaki K, Suzushima H, Ohno Y, Matsuoka H, Jo T, Amano M, Hino R, Shimokawa M, Kawai K, Suzumiya J, Tamura K; ATL-Prognostic Index Project.

Blood. 2015 Dec 10;126(24):2570-7. doi: 10.1182/blood-2015-03-632489. Epub 2015 Sep 11.

PMID:
26361794
41.
42.

Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm.

Aoki T, Suzuki R, Kuwatsuka Y, Kako S, Fujimoto K, Taguchi J, Kondo T, Ohata K, Ito T, Kamoda Y, Fukuda T, Ichinohe T, Takeuchi K, Izutsu K, Suzumiya J.

Blood. 2015 Jun 4;125(23):3559-62. doi: 10.1182/blood-2015-01-621268. Epub 2015 Apr 27.

PMID:
25918345
43.

Validity of the chemotherapy-induced peripheral neuropathy self-check sheet.

Miyoshi Y, Onishi C, Fujie M, Senoo N, Wakatsuki R, Suzumiya J.

Intern Med. 2015;54(7):737-42. doi: 10.2169/internalmedicine.54.3318. Epub 2015 Apr 1.

44.

[Anti-CD20 antibody].

Jo Y, Suzumiya J.

Nihon Rinsho. 2015 Feb;73 Suppl 2:204-8. Japanese. No abstract available.

PMID:
25831753
45.

Synergistic combination therapy with cotylenin A and vincristine in multiple myeloma models.

Takahashi T, Honma Y, Miyake T, Adachi K, Takami S, Okada M, Kumanomidou S, Ikejiri F, Jo Y, Onishi C, Kawakami K, Moriyama I, Inoue M, Tanaka J, Suzumiya J.

Int J Oncol. 2015 Apr;46(4):1801-9. doi: 10.3892/ijo.2015.2882. Epub 2015 Feb 9.

PMID:
25672400
46.

The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.

Kako S, Izutsu K, Kato K, Kim SW, Mori T, Fukuda T, Kobayashi N, Taji H, Hashimoto H, Kondo T, Sakamaki H, Morishima Y, Kato K, Suzuki R, Suzumiya J; Adult Lymphoma Working Group of the Japanese Society for Hematopoietic Cell Transplantation.

Am J Hematol. 2015 Feb;90(2):132-8. doi: 10.1002/ajh.23897. Epub 2014 Nov 24.

47.

Haematopoietic stem cell transplantation for relapsed or refractory anaplastic large cell lymphoma: a study of children and adolescents in Japan.

Fukano R, Mori T, Kobayashi R, Mitsui T, Fujita N, Iwasaki F, Suzumiya J, Chin M, Goto H, Takahashi Y, Hara J, Park YD, Inoue M, Koga Y, Inagaki J, Sakamaki H, Adachi S, Kawa K, Kato K, Suzuki R.

Br J Haematol. 2015 Feb;168(4):557-63. doi: 10.1111/bjh.13167. Epub 2014 Oct 14.

PMID:
25312752
48.

Internal tandem duplication mutations in FLT3 gene augment chemotaxis to Cxcl12 protein by blocking the down-regulation of the Rho-associated kinase via the Cxcl12/Cxcr4 signaling axis.

Onishi C, Mori-Kimachi S, Hirade T, Abe M, Taketani T, Suzumiya J, Sugimoto T, Yamaguchi S, Kapur R, Fukuda S.

J Biol Chem. 2014 Nov 7;289(45):31053-65. doi: 10.1074/jbc.M114.568287. Epub 2014 Sep 18. Erratum in: J Biol Chem. 2015 Nov 20;290(47):28356. Onish, Chie [corrected to Onishi, Chie].

49.

[Marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type (MALT lymphoma)].

Takahashi T, Suzumiya J.

Nihon Rinsho. 2014 Mar;72(3):493-8. Japanese.

PMID:
24724410
50.

Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.

Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, Suzumiya J, Inagaki H, Tamura K, Akinaga S, Tomonaga M, Ueda R.

J Clin Oncol. 2014 Apr 10;32(11):1157-63. doi: 10.1200/JCO.2013.52.0924. Epub 2014 Mar 10.

PMID:
24616310

Supplemental Content

Loading ...
Support Center